Memphasys (ASX:MEM) has confirmed that its commercial operations across the Middle East and North Africa remain entirely uninterrupted despite ongoing geopolitical instability in the region.
The company announced that its supply chains, distribution networks, and customer engagement activities continue to function at full capacity with no material disruptions identified.
The resilience is underscored by a diversified commercial strategy designed to reduce reliance on any single market, ensuring that demand and order activity remain consistent with internal expectations.
A primary driver of this stability is the company’s established presence in Qatar.
Operations there remain fully functional, with the Hamad Medical Corporation continuing the routine clinical use of the Felix System.
The ongoing adoption by a premier institutional customer provides a stable foundation of recurring revenue through consistent cartridge consumption.
Beyond Qatar, Memphasys is aggressively expanding its regional footprint with its distribution partner, ITL.
The company has secured new commercial orders from customers in the United Arab Emirates and Iraq, signalling strong regional momentum.
Further growth is anticipated in Egypt and Turkey, where Memphasys is currently progressing through regulatory approval pathways.
A reseller partnership has been confirmed in Egypt, with initial trial orders expected next quarter, while Turkey is also slated for its first commercial orders in the same period.